Facts
Is this your organization? Claim it
Recent coverage
Front-page news, podcasts and videos about Fierce Biotech
Neoleukin Therapeutics Cuts 70% of Workforce, CEO Jonathan Drachman to Step Down Amid Strategic Review
Neoleukin Therapeutics is cutting about 70% of its workforce and exploring strategic alternatives including sale or merger, with CEO Jonathan Drachman stepping down. The company’s stock rose by over 30% following the announcement.
Century Therapeutics Cuts 25% Staff, Closes Seattle and Hamilton Sites, R&D Head Hyam Levitsky to Resign by Jan 31
Century Therapeutics is closing its Seattle hub and cutting 25% of its workforce, including a shutdown of its Hamilton, Ontario location, as it shifts priorities and extends its cash runway to 2026. The company’s president of R&D, Hyam Levitsky, plans to resign by January 31, and Century is de-prioritizing programs for glioblastoma and blood cancers.
By Fierce Biotech
BrainChild Bio raises $116M Series A from Seattle Children’s and WRF to fund pivotal CAR-T trial for DIPG
BrainChild Bio, spun out of Seattle Children’s Hospital, raised $116 million in a Series A led by Seattle Children’s and WRF Capital to fund a pivotal phase 2 trial of CAR-T candidate BCB-276 for diffuse intrinsic pontine glioma (DIPG) and advance a planned phase 1 glioblastoma program.
Talus Bio raises $11.2M seed+ to advance MARMOT platform and target hard-to-reach transcription factors in cancer
Talus Bio raised $11.2 million to advance preclinical cancer programs and expand its MARMOT discovery platform that uses AI, proteomics, synthetic chemistry, and computational biology to target difficult transcription factors driving cancers including prostate cancer and brachyury-driven chordoma.
CurvaFix Raises $39M Led by MVM Partners, Appoints Mark Foster as CEO to Scale U.S. Sales of Curved Intramedullary Pelvic Implants
CurvaFix raised $39 million in a venture round led by MVM Partners to expand U.S. availability of its curved intramedullary implants for pelvic fragility fractures, bringing its total VC funding to over $50 million; the company also appointed Mark Foster, an experienced medtech executive, as CEO to scale sales.